Expertise in
9
conditions

Dr. Barry Byrne

Pediatrics
UF Health Center For Pediatric Neuromuscular And Rare Diseases
1549 Gale Lemerand Dr Fl Second, 
Gainesville, FL 
Expertise in
9
conditions
UF Health Center For Pediatric Neuromuscular And Rare Diseases
1549 Gale Lemerand Dr Fl Second, 
Gainesville, FL 

Overview

Barry Byrne is a Pediatrics provider in Gainesville, Florida. Dr. Byrne is highly rated in 9 conditions, according to our data. His top areas of expertise are Pompe Disease, Barth Syndrome, Becker Muscular Dystrophy, Duchenne Muscular Dystrophy, and Bone Marrow Aspiration.

His clinical research consists of co-authoring 199 peer reviewed articles and participating in 20 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Pediatrics

Licenses

Pediatric Cardiology in FL

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

UF Health Center for Pediatric Neuromuscular and Rare Diseases
1549 Gale Lemerand Dr Fl Second, Gainesville, FL 32610
Other Locations
UF Health Pediatric Infusion Center & Specialties Clinic
1600 SW Archer Rd Fl Fourth, Gainesville, FL 32610

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

A Randomized, Controlled, Open-label, Single-ascending Dose, Phase I/II Study to Investigate the Safety and Tolerability, and Efficacy of Intravenous SGT-001 in Male Adolescents and Children With Duchenne Muscular Dystrophy
A Randomized, Controlled, Open-label, Single-ascending Dose, Phase I/II Study to Investigate the Safety and Tolerability, and Efficacy of Intravenous SGT-001 in Male Adolescents and Children With Duchenne Muscular Dystrophy
Enrollment Status: Active_not_recruiting
Publish Date: February 03, 2026
Intervention Type: Genetic
Study Drug: SGT-001 Adeno-Associated Virus Microdystrophin Construct
Study Phase: Phase 1/Phase 2
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: November 18, 2025
Intervention Type: Drug
Study Drugs: SRP-4045 Exon 45-Skipping Treatment, SRP-4053 Exon 53-Skipping Treatment
Study Phase: Phase 3
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
An Open-Label, Fixed-Sequence, Ascending-Dose, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous Infusions of ATB200 Co-Administered With Oral AT2221 in Adult Subjects With Pompe Disease
Enrollment Status: Completed
Publish Date: October 23, 2025
Intervention Type: Drug
Study Drugs: ATB200, AT2221
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: August 26, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Natural History Study in Children With a TECPR2 Mutation
A Natural History Study in Children With a TECPR2 Mutation
Enrollment Status: Completed
Publish Date: September 11, 2023
Expanded Access Trial of Systemic Delivery of Aspartoacylase ASPA (rAAV9-CB6-AspA) Gene Vector in a Single Patient With Canavan Disease
Expanded Access Trial of Systemic Delivery of Aspartoacylase ASPA (rAAV9-CB6-AspA) Gene Vector in a Single Patient With Canavan Disease
Enrollment Status: No_longer_available
Publish Date: August 23, 2023
Intervention Type: Drug
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: February 02, 2023
Intervention Type: Drug
Study Drug: Givinostat
Study Phase: Phase 3
A Phase 1 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment
A Phase 1 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment
Enrollment Status: Completed
Publish Date: July 06, 2022
Intervention Type: Drug
Study Phase: Phase 1
Evaluation of Re-administration of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase (rAAV9-DES-hGAA) in Patients With Late-Onset Pompe Disease (LOPD)
Evaluation of Re-administration of Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase (rAAV9-DES-hGAA) in Patients With Late-Onset Pompe Disease (LOPD)
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Drug, Other, Genetic
Study Drugs: Rapamycin, Rituxan, Diphenhydramine, Acetaminophen, Lidocaine, LMX 4 Topical Cream, Adeno-Associated Virus Acid Alpha Glucosidase
Study Phase: Phase 1
A Phase II, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: December 07, 2021
Intervention Type: Drug
Study Phase: Phase 2
A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-Term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-Term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: May 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Pilot Study of Diet and Exercise Therapy in Pompe Disease
A Pilot Study of Diet and Exercise Therapy in Pompe Disease
Enrollment Status: Completed
Publish Date: May 14, 2021
Intervention Type: Other
Study Phase: Not Applicable
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: July 23, 2019
Intervention Type: Drug
Study Phase: Phase 2
Assessment of Cardiopulmonary Function in Duchenne Muscular Dystrophy
Assessment of Cardiopulmonary Function in Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: July 08, 2019
Intervention Type: Other
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: January 02, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Pilot Study of the Effects of Oral Administration of Zavesca® on Anti-rhGAA Immune Response in Subjects With Pompe Disease Receiving rhGAA Enzyme Replacement Therapy
A Pilot Study of the Effects of Oral Administration of Zavesca® on Anti-rhGAA Immune Response in Subjects With Pompe Disease Receiving rhGAA Enzyme Replacement Therapy
Enrollment Status: Terminated
Publish Date: December 05, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects With Late-onset Pompe Disease
A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects With Late-onset Pompe Disease
Enrollment Status: Terminated
Publish Date: June 14, 2018
Intervention Type: Drug
Study Phase: Phase 3
Effects of Immunomodulation Therapy on Anti-rhGAA Immune Response in Subjects With Pompe Disease Receiving rhGAA Enzyme Replacement Therapy
Effects of Immunomodulation Therapy on Anti-rhGAA Immune Response in Subjects With Pompe Disease Receiving rhGAA Enzyme Replacement Therapy
Enrollment Status: Completed
Publish Date: December 08, 2017
Intervention Type: Drug
View 19 Less Clinical Trials

199 Total Publications

Meeting report: 2024 Muscular Dystrophy Association summit on 'Safety and challenges in gene therapy of neuromuscular diseases'.
Meeting report: 2024 Muscular Dystrophy Association summit on 'Safety and challenges in gene therapy of neuromuscular diseases'.
Journal: Journal of neuromuscular diseases
Published: January 19, 2026
Similar Doctors
Expertise in
3
conditions
Dr. Dipankar Gupta
Pediatric Cardiology | Pediatrics
Expertise in
3
conditions
Dr. Dipankar Gupta
Pediatric Cardiology | Pediatrics

Florida Clinical Practice Association Inc

1600 Sw Archer Rd, 
Gainesville, FL 
 (0.1 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Dipankar Gupta is a Pediatric Cardiologist and a Pediatrics provider in Gainesville, Florida. Dr. Gupta is highly rated in 3 conditions, according to our data. His top areas of expertise are Hypoplastic Left Heart Syndrome (HLHS), Transposition of the Great Arteries, Pediatric Myocarditis, Mitral Stenosis, and Heart Transplant. Dr. Gupta is currently accepting new patients.

Expertise in
2
conditions
Dr. Eric Nelson
Pediatrics
Expertise in
2
conditions
Dr. Eric Nelson
Pediatrics

Uf Health Medical Lab-Shands Hospital

1600 SW Archer Rd, 
Gainesville, FL 
 (0.1 miles away)
352-273-5400
Languages Spoken:
English
See accepted insurances

Eric Nelson is a Pediatrics provider in Gainesville, Florida. Dr. Nelson is highly rated in 2 conditions, according to our data. His top areas of expertise are Diarrhea and Undescended Testicle.

Expertise in
4
conditions
Dr. Josef P. Neu
Neonatology | Pediatrics
Expertise in
4
conditions
Dr. Josef P. Neu
Neonatology | Pediatrics
1600 Sw Archer Road, Box 100371, 
Gainesville, FL 
 (0.1 miles away)
352-392-4193
Languages Spoken:
English
See accepted insurances

Josef Neu is a Neonatologist and a Pediatrics provider in Gainesville, Florida. Dr. Neu is highly rated in 4 conditions, according to our data. His top areas of expertise are Necrotizing Enterocolitis, Premature Infant, Viral Gastroenteritis, Cerebral Hypoxia, and Osteotomy.

Frequently Asked Questions about Dr. Barry Byrne

How do I make an appointment with Dr. Barry Byrne?

You can book an appointment with Dr. Barry Byrne by calling their office at 877-543-7783. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Barry Byrne a top-rated expert for Pompe Disease?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Barry Byrne is classified as an Elite expert for Pompe Disease, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Barry Byrne specialize in?

While Dr. Barry Byrne is a Pediatrics, they have specific expertise in Pompe Disease, Barth Syndrome, and Becker Muscular Dystrophy. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatrics.

Does Dr. Barry Byrne participate in research or clinical trials?

Yes. Dr. Barry Byrne has published 199 articles and abstracts on conditions like Pompe Disease. You can view a list of Dr. Barry Byrne's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Barry Byrne accept my insurance?

Dr. Barry Byrne accepts most major insurance plans, including Blue Shield of California and Florida Blue. We recommend calling the office directly at 877-543-7783 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Byrne's expertise for a condition
ConditionClose
View All 7 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile